BOIRON

BOI

FR0000061129

Pharmaceuticals

Real-time Euronext Paris Other stock markets 03:00:24 2025-12-11 am EST			5-day change	1st Jan Change
30.60 ^EUR	+2.00%		-3.47%	+14.18%

Nov. 21	Thierry Boiron Steps Down as Deputy CEO of Boiron
Nov. 20	Thierry Boiron steps down as deputy CEO of Boiron SA	RE

Boiron: changes in governance

Published on 07/04/2024 at 07:40 am EDT - Modified on 07/04/2024 at 07:43 am EDT

- Translated by Marketscreener - See original

BOIRON

+2.00%

Boiron announces a change in its governance, with the appointment of Thierry Boiron as CEO to replace Valérie Lorentz- Poinsot, who is concurrently resigning from her directorship.

Anabelle Flory-Boiron, who worked for the homeopathic laboratory for 19 years until December 2021 and has been a director since 2020, has been appointed Chairman of the Board of Directors, replacing Thierry Boiron.

Copyright (c) 2024 CercleFinance.com. All rights reserved.

Latest news about BOIRON

Nov. 21	Thierry Boiron Steps Down as Deputy CEO of Boiron
Nov. 20	Thierry Boiron steps down as deputy CEO of Boiron SA	RE
Sep. 19	Today's market movers: sharp rises for Nexity, Embla, and Spire, falls for Maersk and LSEG
Sep. 19	On Wall Street, it's four records for the price of one
Sep. 19	Boiron H1 profit more than triples
Sep. 18	Boiron SA(ENXTPA:BOI) dropped from CAC Small Index	CI
Sep. 18	Boiron SA(ENXTPA:BOI) dropped from CAC All-Tradable Index	CI
Sep. 18	Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
Sep. 18	Boiron H1 net income group part EUR 11.4 mln	RE
Sep. 11	Euronext: quarterly review of CAC family	RE
Apr. 22	Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
Apr. 14	Boiron SA announces Annual dividend, payable on June 05, 2025	CI
Apr. 04	Boiron: 68% drop in annual NI
Apr. 03	Boiron FY Operating Income EUR 15.7 Million	RE
Dec. 12	Boiron: appointment of a new CEO
Nov. 22	Boiron: 145 additional job cuts
24-09-22	Boiron SA(ENXTPA:BOI) dropped from S&P Global BMI Index	CI
24-09-20	Boiron: fall in 1st half results
24-09-05	Such a long wait
24-08-18	Boiron SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-04	Boiron: changes in governance
24-04-25	Boiron SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-02	Boiron: nearly 600,000 shares tendered to the OPAS
24-01-11	Boiron: OPAS open from January 11 to 31
23-10-13	Boiron: Orfim crosses the 5% threshold

Chart BOIRON

Duration

Period

BOI: Dynamic Chart

Company Profile

Laboratoires BOIRON was founded in France almost a century ago, under the impetus of homeopathic doctors who wanted to benefit from the most reliable medicines possible. Homeopathic medicines have many advantages in that they can be prescribed and advised in first line whenever relevant, in both urban and hospital settings. All actions aim to contribute to major public health issues. Homeopathic medicines are obtained from substances called homeopathic strains, according to a manufacturing process described in the pharmacopoeia. These strains can be of plant, animal, mineral or chemical origin. There are two main families of homeopathic medicines: common name homeopathic medicines and brand name homeopathic medicines (specialties). BOIRON group centralizes its production and logistics in France. It also has 26 wholly-owned or leased distribution facilities in France and various offices in the countries where it has subsidiaries. Net sales are distributed geographically as follows: France (44.8%), Europe (25.3%), North America (25.9%) and other (4%).

Employees

2,736

Sector

Pharmaceuticals

Calendar

Mar. 17 - Q4 2025 Earnings Release (Projected)

More about the company